Tiny Cambridge startup backed by Termeer launches trial of ALS drug
August 08, 2017 at 14:51 PM EDT
Current treatment options for ALS leave "a pretty tremendous unmet need," Amylyx Pharmaceuticals CEO Joshua Cohen said in an interview after the company announced the start of the trial.
